Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Dose-response analysis for boron neutron capture therapy of the B16 murine melanoma using p-boronophenylalanine

Conference ·
OSTI ID:5546307

Boron Neutron Capture Therapy (BNCT) of a well-pigmented B16 melanoma implanted subcutaneously in the mouse thigh has been carried out at the Brookhaven Medical Research Reactor (BMRR) using the synthetic amino acid p-boronophenylalanine (BPA) as the boron delivery agent. The response of the B16 melanoma to BNCT was compared with the response to 250 kVp x-rays using both tumor growth delay and in vivo/in vitro assay that measures clonogenic survival. These experiments allow a comparison of tumor growth delay, log cell kill and damage to normal tissues produced by BNCT or photon irradiation.

Research Organization:
Brookhaven National Lab., Upton, NY (USA)
Sponsoring Organization:
DOE; NIOSH; USDOE, Washington, DC (USA); National Inst. for Occupational Safety and Health, Rockville, MD (USA)
DOE Contract Number:
AC02-76CH00016
OSTI ID:
5546307
Report Number(s):
BNL-46150; CONF-901226--5; ON: DE91013806; CNN: CA42446 (JAC)
Country of Publication:
United States
Language:
English

Similar Records

Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine
Conference · Sun Dec 31 23:00:00 EST 1989 · OSTI ID:5643007

Radiobiology of boron neutron capture therapy: Problems with the concept of relative biological effectiveness
Conference · Sun Dec 31 23:00:00 EST 1989 · OSTI ID:5768887

Neutron capture therapy for melanoma
Conference · Thu Dec 31 23:00:00 EST 1987 · OSTI ID:5468867